The acceptance of the late-breaking abstract for the AspyreRx trial outcomes signifies positive progress in Better Therapeutics' research and development efforts. Participation in the 17th International Conference on Advanced Technologies & Treatments for Diabetes and hosting a sponsored session could enhance the company's reputation and credibility in the healthcare and investor communities. This combination of factors is likely to have a positive short-term impact on BTTX's stock price as it highlights the company's active role in advancing diabetes treatment and its commitment to healthcare innovation.